Lorlatinib
Sign in to save this workspacePrimary targets: ALK · FDA status: FDA Approved
Selectivity scorecard
KISS
97.24
Gini
0.694
CATDS
0.018
Computed from wild-type kinome inhibition at 1 μM. Gini reproduces the published values within tolerance; KISS and CATDS are computed but pending reconciliation with the paper's reference code.
Polypharmacology radar
Top 20 strongest-inhibited wild-type kinases for Lorlatinib. Strongest target: ROS_ROS1 at 99.5% inhibition.
Accessible data table
| Rank | Target | Inhibition % | Residual activity % |
|---|---|---|---|
| 1 | ROS_ROS1 | 99.5% | 0.5% |
| 2 | ACK1 | 99.3% | 0.7% |
| 3 | FER | 98.1% | 1.9% |
| 4 | FAK_PTK2 | 97.7% | 2.3% |
| 5 | PYK2 | 97.6% | 2.4% |
| 6 | ALK | 97.2% | 2.8% |
| 7 | TYK1_LTK | 93.8% | 6.2% |
| 8 | FES_FPS | 93.7% | 6.3% |
| 9 | GRK7 | 92.0% | 8.0% |
| 10 | TRKC | 91.3% | 8.7% |
| 11 | TRKB | 90.5% | 9.5% |
| 12 | PHKG2 | 88.5% | 11.5% |
| 13 | TNK1 | 87.9% | 12.1% |
| 14 | STK22D_TSSK1 | 86.4% | 13.6% |
| 15 | NEK8 | 81.2% | 18.8% |
| 16 | PLK4_SAK | 80.6% | 19.4% |
| 17 | FRK_PTK5 | 80.0% | 20.0% |
| 18 | CAMKK2 | 79.2% | 20.8% |
| 19 | DCAMKL1 | 77.5% | 22.5% |
| 20 | SLK_STK2 | 73.0% | 27.0% |
Selectivity landscape
Where Lorlatinib sits in the 92-drug selectivity landscape (KISS vs Gini). The highlighted point is Lorlatinib.
Annotations
Sign in to read and post annotations.
Loading…